We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App

Coronavirus Screening Platform Uses Machine Learning Algorithms to Detect SARS-CoV-2 Structural Fingerprint in Real Time

By LabMedica International staff writers
Posted on 27 Aug 2020
Print article
A screening platform that can identify biological threats by shining a laser onto the sample and interpreting the light that scatters is being used to develop a coronavirus screening platform, according to a report by BioSpace.

Botanisol Analytics (Phoenix, AZ, USA) is developing the screening platform that can identify biological threats, including contaminants and pathogens (such as the novel coronavirus), by shining a laser onto the sample. The screener uses next generation Raman spectroscopy, which generates a unique structural ‘fingerprint’ for each molecule or even entire structures, such as whole cells or viruses. The laser interacts with the molecules in the sample, which absorb its energy and emit a higher or lower energy light. A detector collects the new light wavelengths that are emitted and turns them into digital input. A computer interprets the results to produce a Raman spectrum, the unique patterns of scattered light wavelengths represented as peaks. Artificial intelligence can then scan a spectrum to check for any unique patterns related to specific molecules or pathogens.

Using machine learning algorithms, the technology can identify salient differences between healthy and infected cells which could be present in an upper respiratory or saliva sample. As a coronavirus screener, the test output would be if someone is at low or high risk of carrying the virus, allowing people to be quickly grouped for release (low risk) or triage for further testing (high risk), according to BioSpace. The device could screen people for COVID-19 in real time, providing answers about what is in a sample in a matter of minutes. Botanisol’s ‘next generation’ system is also extremely sensitive and is able to detect something in the sample down to parts per million (ppm) or trillion (ppt), thanks to the use of a new type of laser that produces the smallest wavelength able to be transmitted through air under normal conditions, according to the BioSpace report.

“It’s a real-time snapshot of all the molecules in a patient’s sample,” David Talenfeld, JD, MBA, MGM, CEO of Botanisol, told BioSpace. “The device can be calibrated to detect a chemical or pathogen, like coronavirus, whose spectral ‘fingerprint’ is known."

“In the future you could take samples from people getting off of an airplane, quickly screening everyone,” added Talenfeld. “The people identified as ‘high risk’ for carrying coronavirus can be diverted to a special waiting area for further testing.”

Related Links:
Botanisol Analytics

Print article
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.